This study looks at how a study medicine called PF-08653944 affects how quickly the stomach empties food after eating. It is being done in adults who are overweight or have obesity.
Participants will receive the study medicine for a short period, and doctors will measure how the medicine moves through the stomach and monitor safety. The goal is to better understand how this medicine works in the body and to check for any side effects.
The information from this study may help researchers plan future studies of this medicine.
Adults ≥18 years at screening, male or female, generally healthy as determined by medical history, physical examination, laboratory tests, and ECG.
Body mass index (BMI) 27-45 kg/m² and body weight >50 kg (110 lb).
Participants with overweight or obesity
Any form of diabetes, HbA1c ≥6.5%, or fasting plasma glucose ≥126 mg/dL.
Prior exposure to a GLP-1 receptor agonist within 90 days before first dose, or prior participation in a study with PF-08653944.
Parallel
PF-08653944
DrugSubcutaneous Injection
Acetaminophen
DrugOral suspension
6
Treatment groupsSee each treatment group below.
Acetaminophen Pharmacokinetic (PK) Parameters: Maximum observed plasma concentration (Cmax)
To assess the effect of multiple SC doses of PF-08653944 on the plasma PK profile of acetaminophen, a marker for gastric emptying, in healthy adult participants with overweight or obesity.
Acetaminophen PK parameters: Area under the plasma concentration (AUC)
To assess the effect of multiple SC doses of PF-08653944 on the plasma PK profile of acetaminophen, a marker for gastric emptying, in healthy adult participants with overweight or obesity.
Acetaminophen PK parameters: Time to Maximum concentration (Tmax)
Number of participants with Treatment Emergent Adverse Events (TEAEs)
